megestrol / Generic mfg. - LARVOL DELTA

Metformin combined with progesterone improves efficacy and reduces adverse reactions in early endometrial cancer. (PubMed, Am J Transl Res) - "Metformin combined with progesterone exerts excellent clinical efficacy in the treatment of early EC. It can significantly reduce serum tumor marker levels and BMI, and decrease the occurrence of adverse reactions."

Journal • Endometrial Cancer • Oncology • Solid Tumor • CTGF • MMP9

Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma. (PubMed, Biomed Pharmacother) - "Overall, these findings confirm the potential role of Pg in improving EDP-M cytotoxic effects in 2D and 3D ACC models."

Journal • Preclinical • Adrenal Cortex Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (clinicaltrials.gov) - P3 | N=360 | Recruiting | Sponsor: Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Anorexia • Hematological Malignancies • Oncology • Solid Tumor

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial. (PubMed, Nat Cancer) - P2 | "This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 )."

Journal • P2b data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • PGR

Body mass index but not percentage weight loss was associated with the race/ethnicity of patients with advanced lung cancer: a cross-sectional study. (PubMed, Ann Palliat Med) - "In patients with advanced lung cancer, BMI and total weight loss but not percentage change in weight was significantly associated with self-identified race/ethnicity at the time of Palliative Medicine consultation. On multivariate analysis, the percentage loss in weight was significantly influenced by the weight at first encounter but not race/ethnicity. Racial/ethnic variations in BMI but not percentage weight loss should be accounted for when diagnosing cancer cachexia and more research is needed."

IO biomarker • Journal • Observational data • Retrospective data • Cachexia • Lung Cancer • Oncology • Palliative care • Solid Tumor

To evaluate the efficacy and safety of NEPA combined with Megestrol Acetate versus NEPA combined with Dexamethasone in preventing nausea and vomiting caused by T-Dxd in breast cancer patients (ChiCTR) - P4 | N=120 | Not yet recruiting | Sponsor: Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita

New P4 trial • Breast Cancer • Oncology • Solid Tumor

REFLECT registry: a german registry of fertility preservation in low-risk endometrial cancer (ESGO 2026) - "Patients receive progestogen therapy with medroxyprogesterone acetate, megestrol acetate, GnRH analogues or a levonorgestrel-releasing intrauterine device...Furthermore, the study seeks to identify which patients are optimal candidates for fertility-preserving management and to generate prospective data on long-term oncological safety and fertility outcomes.Conclusion The REFLECT registry will generate comprehensive data on oncological safety, hormonal treatment efficacy, and reproductive outcomes in women with low-risk endometrial cancer or hyperplasia with atypia. Findings will inform patient selection, guide clinical decision-making, and support evidence-based fertility-preserving management strategies."

Endometrial Cancer • Oncology • Solid Tumor • PGR

A randomized, multicenter, open-label, phase 2 basket study of CYP11A1 inhibitor opevesostat in participants with selected solid tumors: study design of cohorts B and C of OMAHA-015 (ESGO 2026) - P2 | "In cohort C, approximately 80 participants will be randomly assigned 1:1 to either arm 5: oral opevesostat 5 mg BID plus daily corticosteroids; or arm 6: physician's choice of oral megestrol acetate 80 mg BID, alternating megestrol plus tamoxifen 20 mg BID, or oral letrozole 2.5 mg daily. Secondary end points include overall survival, objective response rate and duration of response per RECIST v1.1 assessed by BICR, as well as safety. OMAHA-015 is currently enrolling participants.Results Trial in progress abstractConclusion Trial in progress abstract"

Clinical • P2 data • Pan tumor • Carcinosarcoma • Endometrial Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor • TP53

Fertility-sparing management of grade 1 endometrioid endometrial carcinoma after initial progesterone resistance in a young obese woman (ESGO 2026) - "Fertility-sparing therapy with oral megestrol acetate (320 mg/day) was initiated...In young women declining surgery, multimodal hormonal management supported by metabolic optimization after bariatric surgery offers a feasible fertility-preserving strategy. The findings highlight the molecular and metabolic interplay between PAX2 loss, obesity, and progestin responsiveness in early endometrial neoplasia."

Clinical • Endometrial Cancer • Oncology • Solid Tumor • PAX2

The Effect of Melatonin on Endometrial Histology in Patients with Endometrial Proliferative Disorders: A Double-Blind Randomized Clinical Trial. (PubMed, Indian J Surg Oncol) - "The control group received 80 mg Megestrol acetate daily, the intervention group received 80 mg Megestrol acetate daily plus 5 mg of melatonin before bedtime for three months...This difference was statistically significant (P<0.05). Adding melatonin to progestin for treatment of endometrial hyperplasia can enhance the treatment response in women with this condition and lead to a higher rate of treatment."

Clinical • Journal • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor

A prospective, randomized, parallel controlled clinical trial of megestrol acetate oral suspension in patients with locally advanced nasopharyngeal carcinoma (ChiCTR) - P=N/A | N=68 | Not yet recruiting | Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospital

New trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Wang Jianliu

New P2 trial • Endometrial Cancer • Oncology • Solid Tumor

A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate versus Placebo for Anorexia in Patients with Unresectable Hepatocellular Carcinoma Receiving TACE Combined with Targeted and Immunotherapy (ChiCTR) - P2 | N=88 | Not yet recruiting | Sponsor: Southern Medical University Southern Hospital; Southern Medical University Southern Hospital

New P2 trial • Anorexia • Cachexia • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients with Cancer Cachexia (ChiCTR) - P=N/A | N=495 | Not yet recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital

New trial • Anorexia • Cachexia • Oncology

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. (PubMed, Gynecol Oncol) - P2 | "These results support a potential role of the palbociclib-letrozole combination as treatment for hormone receptor-positive advanced/recurrent endometrial cancer. Based on these encouraging results, phase III evaluation of letrozole combined with a CDK4/6 inhibitor is planned."

Journal • Metastases • P2 data • Breast Cancer • Endometrial Cancer • Hematological Disorders • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • CCNA2 • ER

Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P3 | N=68 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P3 trial • Cachexia • Hepatocellular Cancer • Oncology • Solid Tumor

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov) - P2 | N=51 | Active, not recruiting | Sponsor: Northwestern University | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. (PubMed, Gynecol Oncol) - "EL and MT demonstrated clinically meaningful efficacy in recurrent EC patients. The higher PFS observed in chemo-naïve patients is worthy of confirmation in future studies."

Journal • P2 data • Cardiovascular • Endometrial Cancer • Hematological Disorders • Mucositis • Oncology • Solid Tumor

Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). (PubMed, J Gynecol Oncol) - P2/3 | "Compared with MA alone, the addition of LNG-IUS may not improve the early CR rate for EEC, and may produce more adverse events instead."

Journal • P2 data • Endometrial Cancer • Gynecology • Hematological Disorders • Long-acting Reversible Contraceptives • Oncology • Solid Tumor • Uterine Cancer

Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction (SABCS 2023) - "Addition of the PR agonist megestrol enhanced the anti-proliferative effect of letrozole in this window-of opportunity trial. Megestrol combinations were well tolerated, and the anti-proliferative effect was observed in both low and high dose arms. These data support the potential use of low-dose megestrol as an inexpensive and well-tolerated means of improving aromatase inhibitor efficacy."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • AR • AURKA • CASP3 • ER • HER-2 • PGR

PIONEER: A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (clinicaltrials.gov) - P2; N=189; Recruiting; Sponsor: Cambridge University Hospitals NHS Foundation Trust; Trial completion date: Dec 2021 ➔ Nov 2022; Trial primary completion date: Sep 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • AR • AURKA • CASP3 • CDH1 • ER • FN1 • HER-2 • PGR

Alternating Use of Single-Agent Megestrol in Recurrent Endometrial Cancer (SGO 2026) - No abstract available

Endometrial Cancer • Oncology • Solid Tumor

A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Second Xiangya Hospital of Central South University

New P1 trial • Cachexia • Cervical Cancer • Oncology • Solid Tumor

FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov) - P2/3 | N=260 | Not yet recruiting | Sponsor: Fudan University

dMMR • MSI-H • New P2/3 trial • P53mut • Tumor mutational burden • Endometrial Cancer • Oncology • Solid Tumor • ER • MSI • PD-L1 • POLE

Real-World Safety of Cyproheptadine-Based Appetite Stimulants: An Electronic Health Record-Based Retrospective Cohort Study in Adult Patients. (PubMed, J Clin Med) - "Similar findings were noted in the comparison with antihistamines, where the aHRs for dizziness, sedation, or hypotension of 0.56 (0.41-0.78), 1.05 (0.46-2.38), and 0.65 (0.36-1.17), respectively. CAS demonstrated an acceptable safety profile in older adults, with safety comparable to both megestrol and antihistamines."

Journal • Real-world evidence • Retrospective data • Anesthesia • Hypotension • Sarcopenia